Summary Table for Treating Acute Asthmatic Attack in Pediatric Patients
Therapeutic Approach | Age Group | Dosage/Administration | Comments |
Inhaled Short-Acting Beta-2 Agonists (SABA) | |||
Metered-Dose Inhaler (MDI) | <12 years old | 4 to 8 puffs (90 mcg/puff) every 20 minutes for 3 doses, then every 1 to 4 hours as needed | Use a spacer or valve holding chamber. Add a mask for children <4 years old. |
≥12 years old | 4 to 8 puffs (90 mcg/puff) every 20 minutes for 3 doses, then every 1 to 4 hours as needed | Use a spacer or valve holding chamber if needed. | |
Nebulized Solution | <12 years old | 0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses, then 0.15 to 0.3 mg/kg (max 10 mg) every 1 to 4 hours as needed | Use preservative-free solutions. Benzalkonium chloride in multidose bottles may cause bronchoconstriction. |
≥12 years old | 2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to 10 mg every 1 to 4 hours as needed | Use preservative-free solutions. Benzalkonium chloride in multidose bottles may cause bronchoconstriction. | |
Nebulized Solution (Hospital Regimen) | All ages | Ventolin (albuterol) 0.5 ml (2.5 mg) + NSS up to 4 ml, nebulized every 3, 4, or 6 hours depending on severity | Use preservative-free solutions. Benzalkonium chloride in multidose bottles may cause bronchoconstriction. |
Continuous Nebulization | <12 years old | 0.5 mg/kg/hour | Use preservative-free solutions. Benzalkonium chloride in multidose bottles may cause bronchoconstriction. |
≥12 years old | 10 to 15 mg/hour | Use preservative-free solutions. Benzalkonium chloride in multidose bottles may cause bronchoconstriction. | |
Combination Therapy with Ipratropium Bromide | Adding ipratropium bromide to albuterol is recommended for moderate-to-severe exacerbations treated in the ER or acute care. | ||
Systemic Corticosteroids | |||
Intravenous Hydrocortisone | All ages | Initial dose: 2-4 mg/kg, then 2-4 mg/kg/day divided every 6 hours | Useful in reducing inflammation and preventing recurrence of exacerbations. |
Oral Prednisolone | All ages | 1-2 mg/kg/day, divided into 1-2 doses | Effective in managing severe asthma exacerbations. |
Adjunctive Therapies | |||
Magnesium Sulfate | All ages | 25-50 mg/kg IV over 20 minutes (max 2 g) | Used for severe exacerbations unresponsive to initial therapy. |
Aminophylline | All ages | Loading dose: 5-6 mg/kg IV over 20 minutes, Maintenance dose: 0.5-1 mg/kg/hour IV | Consider for refractory cases. |
Monitoring and Support | Continuous monitoring of SpO2, heart rate, respiratory rate | Reassess every 20-30 minutes to evaluate response to treatment. | |
Patient Education and Discharge Planning | Ensure proper use of MDIs and spacers, Provide an asthma action plan, Schedule follow-up appointments | Education on inhaler technique, trigger avoidance, and adherence to treatment plan. |
Introduction
Acute asthmatic attacks in pediatric patients are medical emergencies that require prompt and effective intervention. These attacks are characterized by bronchospasm, airway inflammation, and increased mucus production, leading to severe respiratory distress. This article outlines the pathophysiology, triggers, and comprehensive management strategies for acute asthmatic attacks in children, with a focus on how it differs from viral-induced wheezing.
Pathophysiology and Triggers
Pathophysiology:
Bronchospasm: Constriction of the smooth muscles surrounding the bronchi and bronchioles, triggered by inflammatory mediators such as histamine and leukotrienes.
Airway Inflammation: Swelling of the airway linings due to inflammatory response.
Increased Mucus Production: Hypersecretion of mucus contributing to airway obstruction.
Differences from Viral-Induced Wheezing:
Bronchospasm in Asthma: Primarily involves smooth muscle constriction of the airways in response to allergens, irritants, or exercise, leading to acute narrowing of the airways.
Viral-Induced Wheezing: Typically involves inflammation and edema of the airway lining due to a viral infection, with less emphasis on smooth muscle constriction. Common in young children and may not respond as effectively to bronchodilators alone.
Common Triggers:
Allergens (pollen, dust mites, pet dander)
Respiratory infections (can exacerbate asthma but have distinct mechanisms in viral-induced wheezing)
Cold air and exercise
Air pollutants and tobacco smoke
Management of Acute Asthmatic Attack
1. Initial Assessment and Stabilization:
Airway: Ensure the airway is clear.
Breathing: Administer oxygen if SpO2 < 92%.
Circulation: Monitor heart rate and blood pressure.
2. Bronchodilator Therapy:
Inhaled Short-Acting Beta-2 Agonists (SABA):
Metered-Dose Inhaler (MDI):
<12 years old: 4 to 8 puffs (90 mcg/puff) every 20 minutes for 3 doses, then every 1 to 4 hours as needed.
≥12 years old: 4 to 8 puffs (90 mcg/puff) every 20 minutes for 3 doses, then every 1 to 4 hours as needed.
Nebulized Solution:
<12 years old: 0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses, then 0.15 to 0.3 mg/kg (maximum 10 mg) every 1 to 4 hours as needed.
≥12 years old: 2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to 10 mg every 1 to 4 hours as needed.
Continuous Nebulization:
<12 years old: 0.5 mg/kg/hour.
≥12 years old: 10 to 15 mg/hour.
Combination Therapy with Ipratropium Bromide:
MDI/Nebulizer: Adding ipratropium bromide to albuterol is recommended for moderate-to-severe exacerbations.
3. Systemic Corticosteroids:
Intravenous Hydrocortisone:
Dose: 2-4 mg/kg initially, then 2-4 mg/kg/day divided every 6 hours.
Oral Prednisolone:
Dose: 1-2 mg/kg/day, divided into 1-2 doses.
4. Monitoring and Support:
Continuous Monitoring: SpO2, heart rate, respiratory rate.
Reassessment: Every 20-30 minutes to evaluate response to treatment.
5. Adjunctive Therapies (if needed):
Magnesium Sulfate:
Dose: 25-50 mg/kg IV over 20 minutes (maximum 2 g).
Aminophylline:
Loading Dose: 5-6 mg/kg IV over 20 minutes.
Maintenance Dose: 0.5-1 mg/kg/hour IV.
6. Patient Education and Discharge Planning:
Inhaler Technique: Ensure proper use of MDIs and spacers.
Asthma Action Plan: Provide a written plan for managing future exacerbations.
Follow-up: Schedule follow-up appointments to reassess control and adjust long-term therapy.
Summary
Managing acute asthmatic attacks in pediatric patients requires a structured approach to quickly relieve bronchospasm and reduce inflammation. Albuterol (Ventolin) is the cornerstone of acute treatment, administered via nebulizer or MDI. Systemic corticosteroids like hydrocortisone and prednisolone are essential for reducing inflammation. Continuous monitoring, reassessment, and patient education are crucial components of effective asthma management.
By understanding the differences between asthma-induced bronchospasm and viral-induced wheezing, healthcare providers can tailor their treatment strategies more effectively, ensuring prompt and effective care for pediatric patients experiencing acute asthmatic attacks.
コメント